PRA Health joins with clinical research network to improve vaccine studies

Seeking to accelerate the process of getting new vaccines to market, PRA Health Sciences ($PRAH) partnered with the Alliance for Multispecialty Research (AMR) to look for ways to help vaccine studies run more efficiently and effectively. The deal joins a leading contract research organization and a clinical research network, allowing the two "to make significant strides in implementing efficient solutions to smarter vaccine development," AMR CEO Brenda Atchison said in a statement. Release

Suggested Articles

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.

Participation in clinical trials among Black people is low, FDA statistics show, even as drugmakers prioritize including them in COVID-19 shot trials.